Wein Matthew
See Remarks
Wein Matthew has filed 6 SEC Form 4 filings (7 transaction rows) across 1 company, with disclosures dating back to 2025. 6 of those filings fall inside the rolling window. Most recent filing: Sep 10, 2026.
On the most recent filing, Wein Matthew is listed as See Remarks at Metagenomi Therapeutics, Inc. Inside the rolling window, Wein Matthew reported no open-market purchases and 5 open-market sales totaling $3K in MGX. The largest disclosed transaction in the window is a sale of 482 MGX shares on Mar 5, 2026, worth $771.
Companies traded
Other insiders at MGX
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$3K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Wein Matthew made?
Wein Matthew has filed 6 SEC Form 4 filings (7 transaction rows) across 1 company since 2025.
Which companies does Wein Matthew trade?
Wein Matthew has filed SEC Form 4 disclosures for 1 company, including MGX.
When was Wein Matthew's most recent SEC Form 4 filing?
Wein Matthew's most recent SEC Form 4 filing on Tracefour is dated Sep 10, 2026.
What is Wein Matthew's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Wein Matthew is listed as See Remarks.
What is Wein Matthew's total buy and sell value in the current window?
Inside the rolling retention window, Wein Matthew bought $0 and sold $3K based on SEC Form 4 filings.
What was Wein Matthew's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 482 MGX shares on 2026-03-05, worth $771, per SEC Form 4 filings.